Tacrolimus (Tac) plus methotrexate (MTX) is a standard regimen for graft-versus-host disease (GVHD) prophylaxis. Mycophenolate mofetil (MMF) is sometimes used instead of MTX to minimize toxicity, despite the lack of controlled studies demonstrating efficacy. We conducted a single-center, randomized phase II trial comparing Tac 1 MMF to Tac 1 MTX. Intent-to-treat analyses included 42 patients randomized to Tac 1 MMF and 47 to Tac 1 MTX. Patient characteristics were not different between the study arms. Patients in the Tac 1 MMF arm were less likely to experience severe mucositis, require narcotic analgesia and parenteral nutrition, and had earlier hospital discharge. The Tac 1 MMF arm had the same time to neutrophil recovery, but earlier platelet recovery. The cumulative incidence of grade II-IV acute GVHD (aGVHD) at 100 days was similar (P 5.8), but grade III-IV aGVHD was higher in the Tac 1 MMF arm (19% versus 4%; P 5.03); this was predominantly seen in unrelated donor transplants (26% versus 4%; P 5.04), and less in related donor transplants (11% versus 4%; P 5 n.s.). Moderate or severe chronic GVHD was similar (P 5 .71). There were no significant differences between the arms in relapse, nonrelapse mortality, or overall and relapse-free survivals. MMF was associated with less early toxicity than MTX but was not as effective in preventing severe aGVHD, especially in unrelated donor transplants.
INTRODUCTION
Acute graft-versus-host disease (aGVHD) is a significant complication of allogeneic hematopoietic cell transplantation (HCT), with death directly attribut-able to aGVHD or its treatment occurring in approximately 10% to 20% of patients. Because treatment of established aGVHD can be difficult, the use of effective prophylaxis is of paramount importance. Tacrolimus (Tac), a potent macrolide lactone immunosuppressant, has been evaluated in combination with methotrexate (MTX) and found to be superior to cyclosporine (CsA) with MTX in the prevention of aGVHD in both sibling and unrelated donor transplants [1] [2] [3] . Based on these data, Tac 1 MTX has become the standard prophylactic regimen in many transplant centers. However, Tac 1 MTX prophylaxis is ineffective in many patients. Furthermore, MTX is associated with a number of adverse outcomes, including severe mucositis, delays in neutrophil and platelet recovery, and renal, pulmonary, and hepatic toxicity. In addition, MTX administration is limited by renal dysfunction or ''third spacing'' because of prolonged elimination times, resulting in increased risk of toxicity. Often, doses of MTX must be omitted, which may further jeopardize the efficacy of GVHD prophylaxis. Although some transplant centers have switched to lower, less toxic doses of MTX for GVHD prophylaxis [4] , others have evaluated alternative immunosuppressive agents with the goal of finding a safer and perhaps more efficacious regimen.
Mycophenolate mofetil (MMF) has been utilized in an effort to improve GVHD prophylaxis and reduce toxicity. MMF is an ester prodrug of the immunosuppressant mycophenolic acid. Mycophenolic acid inhibits inosine monophosphate dehydrogenase, resulting in the blockade of de novo purine synthesis, thereby limiting proliferation of lymphocytes [5] . MMF is effective in preventing GVHD in canine models, and the combination of CsA 1 MMF is more effective than either agent alone [6] . The CsA 1 MMF or Tac 1 MMF combinations are commonly used as GVHD prophylaxis in patients undergoing nonmyeloablative (NMA) transplants. MMF has been compared to MTX in 2 small prospective randomized studies in combination with CsA as GVHD prophylaxis in patients undergoing myeloablative (MA) transplant [7, 8] . In the study reported by Bolwell et al. [7] , significant benefits were seen in the MMF arm, including less severe mucositis, shorter time to neutrophil and platelet engraftment, a reduction in use of total parenteral nutrition (TPN) and narcotic analgesia, and shorter hospitalization times, resulting in early termination of the trial. No differences were observed in the incidence of GVHD or survival, but the analysis lacked sufficient power to detect significant differences in these outcomes. The second study by Kiehl et al. [8] compared CsA 1 MTX 6 prednisone to CsA 1 MMF 6 prednisone; this study also demonstrated a reduction in severe mucositis and time to engraftment in the MMF arm. They observed no difference in the incidence and severity of aGVHD between patients treated with 2 g/day of MMF and those receiving MTX; patients receiving 3 g/day of MMF had a slightly higher incidence of grade III-IV aGVHD than the other groups. The combination of Tac 1 MMF has been evaluated as GVHD prophylaxis in both adults and children in singlearm phase II trials after MA or NMA regimens. These studies have shown TAC 1 MMF to be well tolerated when compared to prior experience [9] [10] [11] [12] .
Here, we report results of a prospective, singlecenter, randomized controlled trial comparing Tac 1 MTX to Tac 1 MMF as GVHD prophylaxis. The primary objective was to compare the incidence of severe mucositis between the 2 prophylactic regimens; the secondary objectives were to generate preliminary data on aGVHD and chronic GVHD (cGVHD), engraftment, treatment-related morbidity and mortality, T cell turnover, relapse, and overall survival (OS).
PATIENTS AND METHODS

Patients
Patients undergoing allogeneic HCT from sibling or unrelated donors matched for 10/10 or 9/10 human leukocyte antigen (HLA)-A, -B, -C, -DRB1, and -DQB1 alleles were eligible for this study. The protocol was approved by the University of South Florida institutional review board, and all patients signed informed consent documents. Patients were randomized to Tac 1 MTX or Tac 1 MMF (1:1) via the Interactive Voice Randomization System coordinated by the Bioinformatics Department of the Moffitt Cancer Center. Randomization was stratified based on predefined conditioning regimen intensity. Enrollment occurred between 10/26/05 and 1/31/08, and data analysis reported is as of 1/31/09.
Study Treatment
Tacrolimus
All patients received Tac 0.03 mg/kg/day as a 24hour continuous intravenous (i.v.) infusion beginning on day 23 (day 0 being the anticipated day of HCT). Tac dosing was based on ideal body weight. When the patient was able to tolerate oral medications, the i.v. Tac was converted to oral dosing given twice daily. Tac doses were adjusted to maintain whole blood levels of 5-15 ng/mL. Full-dose Tac was to be given until day 160 (67) when tapering was begun in the absence of GVHD. Provided no GVHD developed, Tac was to be discontinued on day 1180 (614). Tapering schedules were modified at the discretion of the treating physician in the case of relapse/persistence of malignancy or presence of GVHD. Early discontinuation of Tac was considered in the event of thrombotic microangiopathy (TMA) or posterior reversible encephalopathy syndrome.
Methotrexate
Patients randomized to Tac 1 MTX received 15 mg/m 2 i.v. on posttransplant day 11, then 10 mg/m 2 i.v. on days 13, 16, and 111. Per institutional practice, doses were reduced in patients with renal insufficiency defined as a pretransplant measured creatinine clearance below the lower limits of normal (75 mL/ min in women and 95 mL/min in men). In these patients, MTX dosing was reduced in proportion to reduction in creatinine clearance below the median of the normal range (95 mL/min for women and 120 mL/min for men). In addition, MTX dosing was stopped or reduced if patients developed impending oropharyngeal obstruction because of severe mucositis, fluid ''third spacing'' (eg, pleural effusions or ascites), or severe liver dysfunction.
Mycophenolate mofetil
Patients randomized to MMF received 30 mg/kg/ day i.v. in 2 divided doses beginning day 0 at least 2 hours after the end of the infusion of donor cells. Dosing was based on the lesser of adjusted ideal body weight or actual body weight. The i.v. dose was converted to the oral formulation as patients were able to tolerate oral medications. In the absence of GVHD, a tapering schedule was to begin on day 1240 (614) and to be completed on day 1360 (614). Tapering schedules were modified at the discretion of the treating physician in the case of relapse/ persistence of malignancy or presence of GVHD. MMF dosing could be stopped or reduced in the setting of neutropenia or severe gastrointestinal symptoms if no other cause was identified.
Preparative Regimens, Hematopoietic Cell Infusions, and Supportive Care
The majority of patients received fludarabine 40 mg/m 2 /day daily for 4 days, followed each day by i.v. busulfan (Bu/Flu) pharmacokinetically targeted to an AUC of 3500, 5300, or 6000 mmol*min/L per day, depending on patient age, comorbidities, and disease risk. Bu targeted to 3500 mmol*min/L per day was given to patients over the age of 65 years, over 60 if comorbidities were present, and to patients with chronic lymphocytic leukemia. Patients receiving Bu targeted to 6000 mmol*min/L per day were coenrolled on a prospective study evaluating increasing AUC of Bu. The remainder of the patients were treated to a Bu target of 5300 mmol*min/L per day. Other regimens included Flu 40 mg/m 2 /day daily for 4 days followed on the last 2 days by melphalan 70 mg/m 2 /day (Flu/Mel), Flu 30 mg/m 2 /day for 3 days, and total body irradiation (TBI) 200 cGy (Flu/TBI), and IV Bu daily for 4 days with cyclophosphamide 60 mg/kg/day for 2 days (Bu/ Cy). Three patients in the MMF arm and 1 patient in the MTX arm receiving grafts from HLA mismatched donors received Thymoglobulin Ò 7.5 mg/kg over 3 days through day 21. One patient with aplastic anemia with previous exposure to ATG received alemtuzumab 30 mg over 3 days through day -3, as part of conditioning. Two patients in each arm with CD20-positive lymphoid malignancies received rituximab as part of conditioning.
All patients received peripheral blood stem cells (PBSCs) collected from donors who had received filgrastim for priming. Ex vivo T cell depletion was not performed. Hematopoietic cells were infused on day 0.
Antimicrobial prophylaxis consisted of acyclovir, levofloxacin, and either fluconazole or voriconazole. Cytomegalovirus (CMV) was assayed weekly by realtime polymerase chain reaction of blood samples; when positive, patients were treated with preemptive ganciclovir, valganciclovir, or foscarnet. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis infection was given at least twice weekly. Broad-spectrum antibiotics were administered for febrile neutropenic episodes with antifungal therapy added as clinically indicated. Patient-controlled analgesia (PCA) was initiated in patients with severe pain because of mucositis; TPN was administered if patients were unable to meet their nutritional needs. Ursodiol 600-900 mg/day (depending on body weight) was given at the start of conditioning through day 80 to prevent hepatotoxicity. Patients did not routinely receive myeloid growth factors in the immediate posttransplant period. Platelet and/or red blood cell transfusions were given for platelet counts of \10 Â 10 9 /L or hemoglobin \8 g/dL. All blood products were leukocyte filtered and irradiated for all patients; CMV-negative donors were selected for CMV-negative recipients.
Treatment of GVHD was at the discretion of the treating physician based on the severity of GVHD symptomatology. Initial treatment of stage 1-2 skin GVHD usually consisted of topical corticosteroid preparations. Beclomethasone and budesonide were also used as topical therapy for upper and lower gastrointestinal symptoms, respectively. Prednisone (1-2 mg/ kg/day or equivalent) was initiated for treatment of grade II or higher GVHD. Prophylactic agents were continued, and other immunosuppressive agents were added if symptoms were not controlled on corticosteroid therapy or to assist in tapering of corticosteroids.
Endpoint Definition and Assessment
Mucositis
Mucositis was assessed prospectively daily while the patient was hospitalized and graded retrospectively based on nurse and clinician assessments according to the clinical criteria set forth in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 3.0). Start and stop dates for TPN and PCA were recorded. Length of hospitalization was measured from the date of transplant to the date of discharge.
GVHD
Patients were assessed for aGVHD at least weekly until day 100 posttransplant. aGVHD was staged by individual organ and graded according to consensus conference criteria [13] . Skin, intestinal, and/or liver biopsies were obtained, when appropriate, to facilitate the diagnosis. After day 100, patients were assessed at least every 3 months for cGVHD. cGVHD was graded as mild, moderate, or severe based on the National Institutes of Health Consensus Development Project [14] . Patients were censored for the assessment of GVHD at the time of relapse or death. The type and duration of immunosuppressive treatment given for GVHD were recorded. Prophylactic agents were counted as systemic immunosuppressant agents only if they were continued or restarted beyond the diagnosis of GVHD.
Transplant-related organ toxicity and engraftment
Patients were assessed at least weekly until day 100 posttransplant for organ toxicity. Transplant-related organ toxicity was graded using CTCAE version 3.0. Hepatic veno-occlusive disease (also called sinusoidal obstructive syndrome) was diagnosed and staged according to criteria set forth by McDonald et al. [15] . Day of neutrophil engraftment was defined as the first of 3 consecutive days posttransplant that the absolute neutrophil count was .500/mm 3 . Day of platelet engraftment was defined as the first of 3 consecutive platelet count measurements at least 24 hours apart that the platelet count was .20,000/mm 3 without platelet transfusion in the preceding 7 days. Donor chimerism was assessed by analysis of single-tandem repeats on whole marrow and in sorted CD3 1 T cells and CD33 1 granulocytes from the blood on or about days 130, 190, and 1365.
T cell turnover
Blood samples were collected on or about day 30, day 100, and 1 year posttransplant and tested for expression of Ki-67 on CD4 and CD8 T lymphocytes using CD8-FITC, CD4-APC, CD45-PerCP antibodies, and the Ki-67-phycoerythrin-conjugated reagent set (BD Biosciences, San Diego, CA). Ki-67 expression in the gated CD4 1 or CD8 1 populations was based in comparison to cells stained with isotype-matched phycoerythrin-tagged antibody that gave\0.5% background. All samples were analyzed using a FACSCalibur flow cytometer and CellQuest software (both from BD Biosciences, San Jose, CA). Absolute CD4 1 /Ki-67 1 (or other subset) counts were calculated by multiplying the fraction of CD4 1 /Ki-67 1 (or other subset) events among the CD45 1 events by the absolute white blood cell (WBC) count.
Nonrelapse mortality (NRM) and survival
NRM was defined as death from any cause in patients who have no evidence of malignancy at the time of death. Survival was measured from the time of transplant to the time of last contact or death. All patients were followed for at least 1 year or until death, whichever occurred first.
Statistical Analysis
Sample size determination
Sample size was based on the difference in the proportion of patients in each arm who were predicted to develop severe mucositis defined as clinical grade 3 or 4 per the CTCAE. A sample-size of 42 evaluable subjects per study-arm allowed detection of an absolute difference of 30%, which corresponds to a reduction in the incidence of severe mucositis from 60% in the methotrexate arm to 30% in the MMF arm (alpha 5 0.05, power 5 0.80). The absolute difference of 30% was based on that reported by Bolwell et al. [7] and Kiehl et al. [8] .
Analysis of endpoints
All analyses were performed on an intent-to-treat basis. Categoric variables are summarized as frequencies or percentages and compared between groups using the ''N 2 1'' chi-squared test for 2 Â 2 table [16] or Fisher's exact test for the other cases. Continuous variables are summarized as the median and range and compared between groups using the Wilcoxon ranksum test. OS and relapse-free survival (RFS) are estimated using the Kaplan-Meier method and compared between groups using the log-rank test. Cumulative incidences of time to engraftment, aGVHD and cGVHD, as well as relapse and NRM are generated based on the life-table method and compared using the method of Gray [17] .
RESULTS
Patients and Transplant Characteristics
Ninety-two patients were enrolled on the study; 45 were randomized to Tac 1 MMF and 47 to Tac 1 MTX. Two Tac 1 MMF patients were not transplanted and 1 withdrew consent prior to receiving treatment; therefore, 42 Tac1 MMF patients and 47 Tac 1 MTX patients are included in the analyses. One patient in each arm received the other regimen; however, all the analyses are based on intent to treat. No significant differences were found in patient and transplant characteristics between the study arms ( Table 1) . Acute myelogenous leukemia and myelodysplastic syndrome were the most common diagnoses. Ninety percent of patients received conditioning with Flu and MA doses of Bu (AUC targeted to 5300 mmol*min/L per day or greater). Twenty-three patients in each arm received allografts from unrelated donors.
Regimen Compliance
Tacrolimus One (2%) Tac 1 MMF patient and 6 Tac 1 MTX (13%) patients had Tac discontinued because of elevated creatinine, thrombocytopenia, elevated lactate dehydrogenase (LDH), anemia, or red blood cell (RBC) abnormalities consistent with TMA (P 5 .07). Two (4%) Tac 1 MMF patients and 1 (2%) Tac 1 MTX patient without GVHD were able to begin Tac tapering by day 60 according to the protocol, whereas the rest required prolonged therapy for GVHD manifestations (P 5 .49). At the time of analysis, 7 (17%) Tac 1 MMF patients and 8 (17%) Tac 1 MTX patients discontinued Tac in the absence of GVHD (P 5 .96).
MTX
Twenty-one of the 47 patients (45%) had MTX doses reduced per protocol for pretransplant renal insufficiency. MTX was not given to 1 (2%) patient on days 6 and 11 because of hepatic injury, and 9 (20%) patients had their day 11 dose withheld because of severe mucositis. Eight of these patients were started on MMF on day 11 as substitute for GVHD prophylaxis.
MMF
Nine of the 42 patients (21%) had doses tapered or discontinued secondary to cytopenias or gastrointestinal side effects. Four patients (10%) without evidence of GVHD had MMF tapered around day 240 according to the protocol. Seven (17%) patients stopped MMF in the absence of GVHD after day 240, whereas the remaining surviving patients continue on MMF.
Outcomes
Mucositis and early morbidity
Patients on the Tac 1 MMF arm had lower mean grades of mucositis (P \ .05, Figure 1) . The difference in mucositis scores was significant from day 13 until day 20 posttransplant. There was suggestion for a lower incidence (33% versus 53%; P 5 .06) and shorter duration (median 0 day versus 1 day; P 5 .05) of grade 3 or 4 mucositis in the MMF arm. Fewer patients in the Tac 1 MMF arm required PCA for mucositis pain (64% versus 89%; P 5 .005), and the duration of PCA use was shorter in the Tac 1 MMF arm (median 5 days versus 7 days; P 5 .05). Fewer patients in the Tac 1 MMF arm required TPN (36% versus 60%; P 5 .03). The length of hospitalization after transplant was also shorter in patients randomized to Tac 1 MMF (median 17 days versus 19 days; P 5 .04). One patient in each arm developed moderate veno-occlusive disease, which was reversible in both cases. The 2 study arms had similar incidences of gastrointestinal, hematologic, hepatic, cardiac, hemorrhagic, and pulmonary toxicity.
Engraftment
The median day to absolute neutrophil count greater than 500 Â 10 6 /L was 15 in the Tac 1 MMF arm and 16 in the Tac 1 MTX arm (P 5 .29). Platelet recovery was faster in the Tac 1 MMF arm (median 15 days compared to 17 days; P 5 .002). There were no graft failures in either arm. No differences were seen between the arms in donor chimerism in marrow or peripheral blood T cells or granulocytes (data not shown).
T cell turnover
The number of CD4 cells at day 30 was lower in the Tac 1 MMF patients, with a median of 154 Â 10 6 /L (range: 1-602 Â 10 6 /L) compared to 264 Â 10 6 /L (range: 3-937 Â 10 6 /L) (P 5 .02), but no subsequent differences were observed. There were no differences between the arms in either the proportions of the CD4 or CD8 T cells that were positive for Ki-67 or the absolute numbers of Ki-67-positive subsets (data not shown). Chapuis et al. [5] reported that mycophenolate mofetil treatment can eliminate the fraction of rapidly replicating, Ki-67-positive, T cells in HIV patients. Unfortunately, this effect was not observed in this trial of PBSC transplantation.
GVHD
Maximum aGVHD overall grades were higher in the Tac 1 MMF than in the Tac 1 MTX arm (Table 2) (P 5 .01). At day 100, the cumulative incidence of grade II-IV aGVHD was 78% for the Tac 1 MMF and 79% for the Tac 1 MTX arm (P 5 .8, Figure 2A ); however, there was a higher incidence of grade III-IV aGVHD in the Tac 1 MMF arm (19% versus 4%; P 5 .03, Figure 2B ). The majority of overall grade II aGVHD was accounted for by upper gastrointestinal symptoms, equally frequent in both arms. The only significant difference in organ stage between the 2 study arms was the cutaneous involvement with more Tac 1 MMF patients having stage I disease; in addition, a few more patients in the Tac 1 MMF arm had higher stage of liver and lower gastrointestinal disease, thus accounting for the higher incidence of severe disease overall. The difference in more severe aGVHD (grades III-IV) was seen only in patients with unrelated donors (26% with Tac 1 MMF versus 4% with Tac 1 MTX; P 5 .04), whereas there was no difference in grades III-IV aGVHD between arms in patients with sibling donors (11% with Tac 1 MMF versus 4% after Tac 1 MTX; P 5 .41, Figure 2C and D). There was no difference in cumulative incidence of aGVHD or cGVHD between the 37 Tac 1 MTX patients who received all 4 doses of MTX and the 8 patients who received 3 doses of MTX followed by substitute MMF prophylaxis (data not shown).
The distributions of maximum cGVHD grades were similar between the 2 arms ( Table 3 ). The incidence of moderate or severe cGVHD at 1 year was 38% in the Tac 1 MMF patients and 45% in the Tac 1 MTX patients (P 5 .71; Figure 3 ). No differences in cGVHD were seen between arms when analyzed by donor relation. When the prevalence of aGVHD was assessed weekly through day 100, and cGVHD monthly through 1 year, there were no apparent trends for longer disease duration of any degree in 1 arm over the other (data not shown).
Most patients (83% in the Tac 1 MMF arm and 77% in the Tac 1 MTX arm) received topical treatment with beclomethasone and/or budesonide for upper and/or lower gastrointestinal GVHD, respectively. Four (10%) Tac 1 MMF patients and 7 (15%) Tac 1 MTX patients required no systemic therapy for aGVHD or cGVHD. Of those patients who required prednisone therapy for aGVHD or cGVHD, 28 of 38 (74%) Tac 1 MMF patients and 30 of 38 (79%) Tac 1 MTX patients received initial doses of 1 mg/kg/day, whereas 4 of 38 (11%) and 2 of 38 (5%) were treated with 2 mg/kg/day, respectively. The remaining patients were initiated on less than 1 mg/kg/day. During the first 18 months after transplan-tation, the fraction of patients on prednisone was not different in the 2 study arms (Figure 4 ). Second-line therapy for aGVHD was administered to 6 of 34 (18%) Tac 1 MMF patients and 11 of 36 (31%) Tac 1 MTX patients who had received prednisone as primary therapy (P 5 .41). Complete response to second-line therapy was observed in 4 of 6 Tac 1 MMF and 7 of 11 Tac 1 MTX patients (P 5 .9) No patients in either arm had discontinued all systemic immunosuppressive therapy by 1 year.
Relapse and survival
The cumulative incidences of relapse (p 5 .21) and NRM (P 5 .62), and the estimates of OS (P 5 .58) and RFS (P 5 .49) were similar between the arms (Figure 5A-D) . GVHD was a more common cause of death in Tac 1 MMF patients (37% versus 12%; P 5 .05), but other causes of death, including relapsed malignancy and infection, were similar in the 2 arms ( Table 4 ). In subset analysis by donor relation, there were no differences between the arms in relapse, NRM, RFS, or OS. RFS and OS by donor is shown in Figure 6A -D. The 8 Tac 1 MTX patients who were switched to MMF had higher NRM (P 5 .05) and lower OS (P 5 .02), but no difference in relapse (P 5 .84), compared to those patients who received MTX alone.
DISCUSSION
We report here the first prospective, randomized trial comparing MMF with MTX in combination with Tac for GVHD prophylaxis. Results demonstrated that Tac 1 MMF is associated with a modest reduction in mucositis compared to Tac 1 MTX. We observed faster engraftment of platelets in the Tac 1 MMF arm, but no difference in neutrophil engraftment. More patients in the Tac 1 MTX arm required Tac discontinuation because of renal insufficiency or TMA, suggesting an additive nephrotoxic effect of MTX and Tac. Other transplant-related toxicities were similar between the arms. A limitation of this clinical trial is the unblinded assessment of mucositis. The favorable results with less mucositis in the Tac 1 MMF arm, however, are supported by other objective endpoints such as shorter duration of TPN and PCA usage as well as shorter hospitalization, which are clinically relevant to patient comfort, quality of life, and cost of transplantation.
The reduction in mucositis with Tac 1 MMF was seen despite several characteristics of the study population, which predispose to increased toxicity. First, more than 90% of patients received a regimen of Bu Figure 3 . Cumulative incidence of moderate to severe chronic GVHD. targeted to AUC of at least 5300 mmol*min/L daily, and 20% of patients received intensified conditioning with Bu targeted to 6000 mmol*min/L daily. Second, 45% of patients had pretransplant renal insufficiency. To neutralize this factor, patients received doses of MTX reduced in proportion to their creatinine clearance, as MTX clearance approximates creatinine clearance. Third, the median age of patients in this study was 50 years, with 17% of patients over 60 years. These same factors predisposed patients to increased incidence and severity of aGVHD.
The sample size of the study was designed to detect a difference in mucositis between the 2 arms, but the study was not powered to detect small differences in GVHD or other outcomes. However, the average grades of aGVHD and the incidence of grade III-IV aGVHD were higher in the Tac MMF were more likely than the Tac 1 MTX patients to die from GVHD, consistent with the finding that Tac 1 MMF is less effective at preventing the more severe forms of the disease. Any benefit of the Tac 1 MTX arm in preventing GVHD mortality, however, was offset by higher mortality from relapse of malignancy, resulting in similar overall survival between the 2 study arms. The 2 study arms were balanced between sibling and unrelated donors, but worse GVHD outcome was predominantly observed among patients transplanted from unrelated donors. These transplants lead to more frequent and intense GVHD because of known genetic disparity for classical HLA-A, -B, -C, and -DRB1 loci, or low expressing HLA-DRB3/4/5, -DQB1, and -DPB1 loci that, with the exception of DQB1, were not typed in this study [18, 19] . Other patient subsets were not analyzed. These data demonstrate that the combination of Tac 1 MMF has the potential benefits of less early tox-icity than Tac 1 MTX. The lower potency of Tac 1 MMF in preventing severe GVHD, however, is concerning especially in the setting of MA conditioning regimens, PBSCs, and unrelated donor transplantation. Under these conditions, other forms of prophylaxis should be considered. Subsequent controlled studies should test the efficacy of Tac 1 MMF in less stringent conditions such as reduced intensity or NM conditioning regimens, sibling donors, and marrow transplants.
ACKNOWLEDGMENTS
This work was supported in part by a contract from Astellas Pharma US, Inc. (JR-04-004) and National Cancer Institute Grant 3 P30-CA7692.
Financial disclosure: Janelle Perkins and Teresa Field received financial support from Astellas Pharma 
